secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001051514-22-000091
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Q3 2022 revenue $9.4M (+22% YoY); net loss widens; launches TheraClear X
-------------------------------------------------------------------------------

- Revenue $9.4M vs $7.7M YoY (+22%); equipment revenue $3.6M (+80%); international sales $3.3M (+82%).
- Net loss $1.0M ($0.03/sh) vs $0.5M loss ($0.02/sh) in Q3 2021; non-GAAP adjusted EBITDA $1.1M up from $0.9M.
- Gross margin 61.6% (GAAP) vs 69.7% YoY; non-GAAP gross margin 67.0% vs 71.6%, impacted by amortization and product mix.
- U.S. commercial launch of TheraClear X acne therapy system targeting a $5.5B acne treatment market.
- Reiterates FY2022 revenue guidance of $33M–$35M, expects strong double-digit year-over-year growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/0001051514-22-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000105151422000091/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001051514-22-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer